Persistent triple antiphospholipid antibody positivity as a strong risk factor of first thrombosis, in a long‐term follow‐up study of patients without history of thrombosis or obstetrical morbidity
Abstract
Introduction The long-term risk of first thrombosis and benefit of prophylaxis in antiphospholipid antibody (aPL) carriers without history of thrombosis or obstetrical morbidity is poorly known. This study aimed to evaluate the long-term rate and risk factors associated with a first thrombosis in those patients. Patients and methods After a prior study ended in December 2005 and was already published, we extended the follow-up period of our cohort of aPL carriers. Results Ninety-eight of the 103 patients of the previous study were included. The annual first thrombosis rate was 2.3% per patient-year during a median of 13 years (6-17). None of the baseline characteristics was predictive of risk of first thrombosis, but persistent aPL over time were associated with an increased risk. The stronger association was found in triple aPL-positive carriers: OR 3.38 (95% CI: 1.24-9.22). Of note, conversely to our previous findings, no benefit of aspirin prophylaxis was observed. Conclusion The risk of first thrombosis in aPL carriers without history of thrombosis or obstetrical morbidity was significant, persisted linearly over time and was associated with persistent aPL. This risk was especially increased in triple aPL-positive carriers, in whom a close follow-up seems to be necessary. Nevertheless, the benefit of aspirin prophylaxis remained unclear.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
A long-term follow-up study found that in triple-positive patients, aPL persistence over time carried the highest thrombosis risk.
“A recent long-term follow-up study reported persistence of aPL over time to be associated with the highest risk of thrombosis in triple-positive patients.79”
Cites
Hochberg, M. C. (1997) · Arthritis & Rheumatism · doi:10.1002/art.1780400928 · Cited by 11,409 · see citing works
MIYAKIS, S., LOCKSHIN, M. D., ATSUMI, T., BRANCH, D. W., BREY, R. L., CERVERA, R., DERKSEN, R. H. W. M., DE GROOT, P. G., KOIKE, T., MERONI, P. L., et al. (2006) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2006.01753.x · Cited by 7,203 · see citing works
Anderson, F. A. (1991) · Archives of Internal Medicine · doi:10.1001/archinte.151.5.933 · Cited by 2,142 · see citing works
Anderson, F. A. (1991) · Archives of Internal Medicine · doi:10.1001/archinte.1991.00400050081016 · Cited by 1,678 · see citing works
Galli, M., Luciani, D., Bertolini, G., & Barbui, T. (2003) · Blood · doi:10.1182/blood-2002-02-0441 · Cited by 974 · see citing works
Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients
Rosove, M. H., & Brewer, P. M. C. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-4-303 · Cited by 700 · see citing works
Clinical course of high‐risk patients diagnosed with antiphospholipid syndrome
PENGO, V., RUFFATTI, A., LEGNANI, C., GRESELE, P., BARCELLONA, D., ERBA, N., TESTA, S., MARONGIU, F., BISON, E., DENAS, G., et al. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03674.x · Cited by 633 · see citing works
Ruiz-Irastorza, G., Cuadrado, M., Ruiz-Arruza, I., Brey, R., Crowther, M., Derksen, R., Erkan, D., Krilis, S., Machin, S., Pengo, V, et al. (2011) · Lupus · doi:10.1177/0961203310395803 · Cited by 506 · see citing works
Epidemiology of the Antiphospholipid Antibody Syndrome
Petri, M. (2000) · Journal of Autoimmunity · doi:10.1006/jaut.2000.0409 · Cited by 468 · see citing works
Pengo, V., Ruffatti, A., Legnani, C., Testa, S., Fierro, T., Marongiu, F., De Micheli, V., Gresele, P., Tonello, M., Ghirarduzzi, A., et al. (2011) · Blood · doi:10.1182/blood-2011-03-340232 · Cited by 465 · see citing works
Finazzi, G., Brancaccio, V., Moia, M., Ciavarella, N., Mazzucconi, M. G., Schinco, P., Ruggeri, M., Pogliani, E. M., Gamba, G., Rossi, E., et al. (1996) · The American Journal of Medicine · doi:10.1016/s0002-9343(96)00060-5 · Cited by 427 · see citing works
Erkan, D., Harrison, M. J., Levy, R., Peterson, M., Petri, M., Sammaritano, L., Unalp‐Arida, A., Vilela, V., Yazici, Y., & Lockshin, M. D. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22663 · Cited by 401 · see citing works
de Laat, B., Derksen, R. H. W. M., Urbanus, R. T., & de Groot, P. G. (2005) · Blood · doi:10.1182/blood-2004-09-3387 · Cited by 378 · see citing works
(2004) · PubMed · Cited by 218 · see citing works
Outcome of patients with anticardiolipin antibodies: a 10 year follow-up of 52 patients
Shah, N. M., Khamashta, M. A., Atsumi, T., & Hughes, G. R. (1998) · Lupus · doi:10.1191/096120398678919624 · Cited by 204 · see citing works
Ruffatti, A., Del Ross, T., Ciprian, M., Bertero, M. T., Salvatore, S., Scarpato, S., Montecucco, C., Rossi, S., Caramaschi, P., Biasi, D., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.142042 · Cited by 184 · see citing works
A prospective study of antibodies to β2‐glycoprotein I and prothrombin, and risk of thrombosis
FORASTIERO, R., MARTINUZZO, M., POMBO, G., PUENTE, D., ROSSI, A., CELEBRIN, L., BONACCORSO, S., & AVERSA, L. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01295.x · Cited by 170 · see citing works
Arnaud, L., Mathian, A., Devilliers, H., Ruffatti, A., Tektonidou, M., Forastiero, R., Pengo, V., Lambert, M., Lefevre, G., Martinez-Zamora, M. A., et al. (2015) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.10.019 · Cited by 146 · see citing works
Mustonen, P., Lehtonen, K. V., Javela, K., & Puurunen, M. (2014) · Lupus · doi:10.1177/0961203314545410 · Cited by 127 · see citing works
Ruffatti, A., Ross, T. D., Ciprian, M., Nuzzo, M., Rampudda, M., Bertero, M. T., Bergia, R., Caramaschi, P., Biasi, D., Capsoni, F., et al. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.096669 · Cited by 106 · see citing works
Incidence of venous thromboembolism in different ethnic groups: a regional direct comparison study
Liao, S., Woulfe, T., Hyder, S., et al. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12464 · Cited by 104 · see citing works
Incidence of a first thromboembolic event in carriers of isolated lupus anticoagulant
Pengo, V., Testa, S., Martinelli, I., Ghirarduzzi, A., Legnani, C., Gresele, P., Passamonti, S. M., Bison, E., Denas, G., Jose, S. P., et al. (2015) · Thrombosis Research · doi:10.1016/j.thromres.2014.10.013 · Cited by 89 · see citing works
Influence of aspirin on the clinical outcomes of 103 anti-phospholipid antibodies-positive patients
Hereng, T., Lambert, M., HACHULLA, E., Samor, M., Dubucquoi, S., Caron, C., Launay, D., Morell‐Dubois, S., Queyrel, V., & Hatron, P. (2007) · Lupus · doi:10.1177/0961203307084724 · Cited by 84 · see citing works
Self-citationTarr, T., Lakos, G., Bhattoa, H. P., Soltész, P., Shoenfeld, Y., Szegedi, G., & Kiss, E. V. (2007) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-007-0009-8 · Cited by 53 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Devreese, K. M. J., de Groot, P. G., de Laat, B., Erkan, D., Favaloro, E. J., Mackie, I., Martinuzzo, M., Ortel, T. L., Pengo, V., Rand, J. H., et al. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15047 · Cited by 439 · see citing works
Devreese, K. M. J., Bertolaccini, M. L., Branch, D. W., de Laat, B., Erkan, D., Favaloro, E. J., Pengo, V., Ortel, T. L., Wahl, D., & Cohen, H. (2025) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2024.10.022 · Cited by 92 · see citing works
- Authors
- Yelnik, C. M., Urbanski, G., Drumez, E., Sobanski, V, Maillard, H., Lanteri, A., Morell-Dubois, S., Caron, C., Dubucquoi, S., Launay, D., Duhamel, A., Hachulla, E., Hatron, P. Y., & Lambert, M.
- Affiliations
- Université de Lille (FR)
- Centre Hospitalier Universitaire de Lille (FR)
- Département de biostatistiques, EA2694, Université Lille 2, CHRU Lille, France
- Université Lille 2, UFR Médecine, Lille, France
- Corresponding author
- Lambert, M
- ORCID
- Venue
- Lupus
- Publisher
- SAGE Publications
- Published
- 2016-07-20
- Volume
- 26
- Issue
- 2
- Pages
- 163-169
- ISSN
- 0961-2033 (ISSN-L)
- 1477-0962
- OpenAlex
- W2489967110
- Cited by
- 73
- References
- 24
- Citations by year
- 2026: 6 · 2025: 6 · 2024: 7 · 2023: 7 · 2022: 6 · 2021: 10 · 2020: 12 · 2019: 6 · 2018: 7 · 2017: 6
- FWCI
- 6.73
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Lupus (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Vasculitis and related conditions
- Keywords
- antiphospholipid antibodies, thrombosis risk factors, long-term follow-up, aspirin prophylaxis, antiphospholipid syndrome, thrombosis incidence
- MeSH terms
- Adult, Aspirin, Female, Fibrinolytic Agents, Follow-Up Studies, Humans, Male, Middle Aged, Retrospective Studies, Risk Factors, Thrombosis, Time Factors, Biomarkers, Multivariate Analysis, Chi-Square Distribution, Linear Models, Proportional Hazards Models, Odds Ratio, Antiphospholipid Syndrome, Treatment Outcome, Antibodies, Antiphospholipid, Disease-Free Survival, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
